COVID-19 has pushed decentralised clinical trials (DCTs) to the forefront of clinical research. From telemedicine and wearable sensors to home health visits and direct-to-patient drug shipments, Kieran Connolly, Rosamund Round and Nick Darwall-Smith at Parexel show why the new capabilities afforded by home-based DCTs have been embraced by patients, sites and sponsors alike.